Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

被引：0
|
作者：
Lebwohl, Mark [1 ]
Lacour, Jean Philippe [2 ]
Liljedahl, Monika [3 ]
Lynde, Charles [3 ]
Morch, Marie [3 ]
Snel-Prento, Anja [3 ]
Thaci, Diamant [4 ]
Warren, Richard B. [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Nice, Dept Dermatol, Nice, France
[3] Leo Pharma, Ballerup, Denmark
[4] Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[5] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
12797
引用
收藏
页码：AB1 / AB1
页数：1
相关论文
共 48 条
  • [1] Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial
    Lebwohl, Mark
    Lacour, Jean-Philippe
    Liljedahl, Monika
    Lynde, Charles
    Morch, Marie Holst
    Snel-Prento, Anja Marieke
    Thaci, Diamant
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB207 - AB207
  • [2] Safety of fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in adolescent patients with psoriasis: Results from a phase 2 trial
    Liljedahl, Monika
    Abramovits, William
    Hoejen, Marie N.
    Teng, Joyce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB271 - AB271
  • [3] Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam
    Lebwohl, Mark
    Lacour, Jean Philippe
    Liljedahl, Monika
    Lynde, Charles
    Morch, Marie
    Snel-Prento, Anja
    Thaci, Diamant
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB187 - AB187
  • [4] Fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% topical therapy shows promise in the long-term management of psoriasis
    Lebwohl, Mark
    August, Benjamin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB143 - AB143
  • [5] Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial
    Eichenfield, L. F.
    Marcoux, D.
    Kurvits, M.
    Liljedahl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (05) : 1098 - 1104
  • [6] A phase 3 randomized, double-blind trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064% (BD) aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance
    Lebwohl, Mark
    Gold, Linda Stein
    Snel, Anja
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB21 - AB21
  • [7] Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: Results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials
    Feldman S.R.
    Matheson R.
    Bruce S.
    Grande K.
    Markowitz O.
    Kempers S.
    Brundage T.
    Wyres M.
    American Journal of Clinical Dermatology, 2012, 13 (4) : 261 - 271
  • [8] Efficacy and Safety of Calcipotriene 0.005% Foam for the Treatment of Plaque-Type Psoriasis Results of Two Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Phase III Clinical Trials
    Feldman, Steven R.
    Matheson, Robert
    Bruce, Suzanne
    Grande, Kimberly
    Markowitz, Orit
    Kempers, Steven
    Brundage, Thomas
    Wyres, Melody
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2012, 13 (04) : 261 - 271
  • [9] Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial
    Guenther, L.
    Takhar, A.
    Megna, M.
    Sebastian, M.
    Nyholm, N.
    Thoning, H.
    Levin, L-A
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (07) : 1054 - 1063
  • [10] Comparison of biologic initiation and health care costs among patients with psoriasis receiving fixed-dose combination halo-betasol-propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion vs calcipotriene 0.005%/betamethasone dipropionate 0.064% (CAL/BD) foam
    Kircik, Leon
    Joseph, George
    Gagnon-Sanschagrin, Patrick
    Bumpass, Brock
    Serra, Elizabeth
    Jacobson, Abby
    Guerin, Annie
    Glick, Brad P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB57 - AB57
12345